Moderna takes a new step.
The American biotech, which has made itself known to the general public with its anti-Covid vaccine, publishes the positive results of its most advanced product, against RSV (respiratory syncytial virus), at the origin in particular of bronchiolitis.
In the latest phase of its clinical trials, Moderna's vaccine, which targets the elderly, achieves an effectiveness rate of 83.7%.
The American biotech is therefore preparing to file its registration dossier with the American health authorities.
“
We anticipate approval by the end of 2023 or the beginning of 2024
”, rejoices Stéphane Bancel, CEO of Moderna.
To discover
Pension reform: calculate the age at which you will finally leave
If Sanofi was the first last November to market an RSV vaccine for infants, Moderna finds itself neck and neck with GSK and Pfizer in the market for the elderly.
His two rivals have already filed their case with the American and European health authorities.
But Moderna does...
This article is for subscribers only.
You have 81% left to discover.
Cultivating your freedom is cultivating your curiosity.
Keep reading your article for €0.99 for the first month
I ENJOY IT
Already subscribed?
Login